110 related articles for article (PubMed ID: 37735968)
1. Ursodeoxycholic acid does not affect the clinical outcome of SARS-CoV-2 infection: A retrospective study of propensity score-matched cohorts.
Marrone G; Covino M; Merra G; Piccioni A; Amodeo A; Novelli A; Murri R; Pompili M; Gasbarrini A; Franceschi F
Liver Int; 2024 Jan; 44(1):83-92. PubMed ID: 37735968
[TBL] [Abstract][Full Text] [Related]
2. Protective effect of ursodeoxycholic acid on COVID-19 in patients with chronic liver disease.
Li Y; Zhu N; Cui X; Lin Y; Li X
Front Cell Infect Microbiol; 2023; 13():1178590. PubMed ID: 37207192
[TBL] [Abstract][Full Text] [Related]
3. Ursodeoxycholic acid is associated with a reduction in SARS-CoV-2 infection and reduced severity of COVID-19 in patients with cirrhosis.
John BV; Bastaich D; Webb G; Brevini T; Moon A; Ferreira RD; Chin AM; Kaplan DE; Taddei TH; Serper M; Mahmud N; Deng Y; Chao HH; Sampaziotis F; Dahman B
J Intern Med; 2023 May; 293(5):636-647. PubMed ID: 37018129
[TBL] [Abstract][Full Text] [Related]
4. Effect of ursodeoxycholic acid on preventing SARS-CoV-2 infection in patients with liver transplantation: a multicenter retrospective cohort study.
Hu L; Zhang H; Huang C; Shen T; Feng Z; Mu F; Xu L; Lin Y; Yue C; Guo K; Tian M; Shi J; Zhang C; Wen P; Cao S; Wang Y; Zhang J; Shi X; Wang Z; He Y; Zhang X; Liu X; Lv Y; Liu Z; Guo W; Wang B
QJM; 2024 Jun; 117(5):339-347. PubMed ID: 37950449
[TBL] [Abstract][Full Text] [Related]
5. Ursodeoxycholic acid does not reduce SARS-CoV-2 infection in newly allogeneic hematopoietic stem cell transplantation recipients: a prospective NICHE cohort.
Gao H; Wang J; Zheng X; Pei X; Zheng Y; Zhai W; Zhang R; Chen X; Ma Q; Wei J; Yang D; Pang A; He Y; Feng S; Cao Y; Jiang E
Front Cell Infect Microbiol; 2024; 14():1324019. PubMed ID: 38505288
[TBL] [Abstract][Full Text] [Related]
6. Ursodeoxycholic acid administration did not reduce susceptibility to SARS-CoV-2 infection in children.
Liu T; Wang JS
Liver Int; 2023 Sep; 43(9):1950-1954. PubMed ID: 37381749
[TBL] [Abstract][Full Text] [Related]
7. Ursodeoxycholic Acid Does Not Improve COVID-19 Outcome in Hospitalized Patients.
Colapietro F; Angelotti G; Masetti C; Shiffer D; Pugliese N; De Nicola S; Carella F; Desai A; Ormas M; Calatroni M; Omodei P; Ciccarelli M; Aliberti S; Reggiani F; Bartoletti M; Cecconi M; Lleo A; Aghemo A; Voza A
Viruses; 2023 Aug; 15(8):. PubMed ID: 37632080
[TBL] [Abstract][Full Text] [Related]
8. Ursodeoxycholic acid may protect from severe acute respiratory syndrome coronavirus 2 Omicron variant by reducing angiotensin-converting enzyme 2.
Lee K; Na Y; Kim M; Lee D; Choi J; Kim G; Kim MS
Pharmacol Res Perspect; 2024 Apr; 12(2):e1194. PubMed ID: 38573021
[TBL] [Abstract][Full Text] [Related]
9. Exploring the impact of ursodeoxycholic acid therapy on COVID-19 in a real-word setting.
Corpechot C; Verdoux M; Frank-Soltysiak M; Duclos-Vallée JC; Grimaldi L
J Med Virol; 2024 Jan; 96(1):e29418. PubMed ID: 38240338
[TBL] [Abstract][Full Text] [Related]
10. Testing the efficacy and safety of BIO101, for the prevention of respiratory deterioration, in patients with COVID-19 pneumonia (COVA study): a structured summary of a study protocol for a randomised controlled trial.
Dioh W; Chabane M; Tourette C; Azbekyan A; Morelot-Panzini C; Hajjar LA; Lins M; Nair GB; Whitehouse T; Mariani J; Latil M; Camelo S; Lafont R; Dilda PJ; Veillet S; Agus S
Trials; 2021 Jan; 22(1):42. PubMed ID: 33430924
[TBL] [Abstract][Full Text] [Related]
11. Ursodeoxycholic acid ameliorates cell migration retarded by the SARS-CoV-2 spike protein in BEAS-2B human bronchial epithelial cells.
Thuy PX; Bao TDD; Moon EY
Biomed Pharmacother; 2022 Jun; 150():113021. PubMed ID: 35658221
[TBL] [Abstract][Full Text] [Related]
12. Effect of ursodeoxycholic acid after self-expandable metal stent placement in malignant distal biliary obstruction: a propensity score-matched cohort analysis.
Okuno M; Iwata K; Mukai T; Ohashi Y; Iwata S; Iwasa Y; Yoshida K; Maruta A; Tezuka R; Ichikawa H; Mita N; Uemura S; Iwashita T; Tomita E; Shimizu M
Gastrointest Endosc; 2023 Apr; 97(4):713-721.e6. PubMed ID: 36328210
[TBL] [Abstract][Full Text] [Related]
13. Interaction of Spike protein and lipid membrane of SARS-CoV-2 with Ursodeoxycholic acid, an in-silico analysis.
Rodal Canales FJ; Pérez-Campos Mayoral L; Hernández-Huerta MT; Sánchez Navarro LM; Matias-Cervantes CA; Martínez Cruz M; Cruz Parada E; Zenteno E; Ramos-Martínez EG; Pérez-Campos Mayoral E; Romero Díaz C; Pérez-Campos E
Sci Rep; 2021 Nov; 11(1):22288. PubMed ID: 34782703
[TBL] [Abstract][Full Text] [Related]
14. Ursodeoxycholic acid therapy and liver transplant-free survival in patients with primary biliary cholangitis.
Harms MH; van Buuren HR; Corpechot C; Thorburn D; Janssen HLA; Lindor KD; Hirschfield GM; Parés A; Floreani A; Mayo MJ; Invernizzi P; Battezzati PM; Nevens F; Ponsioen CY; Mason AL; Kowdley KV; Lammers WJ; Hansen BE; van der Meer AJ
J Hepatol; 2019 Aug; 71(2):357-365. PubMed ID: 30980847
[TBL] [Abstract][Full Text] [Related]
15. Pregnant women with SARS-CoV-2 infection are at higher risk of death and pneumonia: propensity score matched analysis of a nationwide prospective cohort (COV19Mx).
Martinez-Portilla RJ; Sotiriadis A; Chatzakis C; Torres-Torres J; Espino Y Sosa S; Sandoval-Mandujano K; Castro-Bernabe DA; Medina-Jimenez V; Monarrez-Martin JC; Figueras F; Poon LC
Ultrasound Obstet Gynecol; 2021 Feb; 57(2):224-231. PubMed ID: 33320401
[TBL] [Abstract][Full Text] [Related]
16. The independent effects of fatigue and UDCA therapy on mortality in primary biliary cirrhosis: results of a 9 year follow-up.
Jones DE; Al-Rifai A; Frith J; Patanwala I; Newton JL
J Hepatol; 2010 Nov; 53(5):911-7. PubMed ID: 20800924
[TBL] [Abstract][Full Text] [Related]
17. Monoclonal Antibodies for Treatment of SARS-CoV-2 Infection During Pregnancy : A Cohort Study.
McCreary EK; Lemon L; Megli C; Oakes A; Seymour CW;
Ann Intern Med; 2022 Dec; 175(12):1707-1715. PubMed ID: 36375150
[TBL] [Abstract][Full Text] [Related]
18. Fenofibrate normalizes alkaline phosphatase and improves long-term outcomes in patients with advanced primary biliary cholangitis refractory to ursodeoxycholic acid.
Ding D; Ren P; Guo G; Liu Y; Yang C; Zheng L; Jia G; Deng J; Sun R; Wang X; Zhou X; Shang Y; Han Y
Gastroenterol Hepatol; 2023 Nov; 46(9):692-701. PubMed ID: 36632973
[TBL] [Abstract][Full Text] [Related]
19. Bezafibrate Improves GLOBE and UK-PBC Scores and Long-Term Outcomes in Patients With Primary Biliary Cholangitis.
Honda A; Tanaka A; Kaneko T; Komori A; Abe M; Inao M; Namisaki T; Hashimoto N; Kawata K; Takahashi A; Ninomiya M; Kang JH; Arakawa M; Yamagiwa S; Joshita S; Umemura T; Sato K; Kaneko A; Kikuchi K; Itakura J; Nomura T; Kakisaka K; Fujii H; Kawada N; Takikawa Y; Masaki T; Ohira H; Mochida S; Yoshiji H; Iimuro S; Matsuzaki Y; Takikawa H;
Hepatology; 2019 Dec; 70(6):2035-2046. PubMed ID: 30737815
[TBL] [Abstract][Full Text] [Related]
20. Impact of Ursodeoxycholic Acid in Critically Ill Patients With Sepsis: A Retrospective Study.
Al Sulaiman K; Kharbosh A; Bin Salah K; Alsulaiman T; Al Andas N; Aljuhani O; Vishwakarma R
J Pharm Pract; 2023 Jun; 36(3):566-571. PubMed ID: 37189247
[No Abstract] [Full Text] [Related]
[Next] [New Search]
